# Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

> **NCT03238703** · PHASE4 · WITHDRAWN · sponsor: **Fred Hutchinson Cancer Center**

## Conditions studied

- HER2/Neu Negative
- Invasive Breast Carcinoma
- Postmenopausal
- Stage 0 Breast Cancer
- Stage IA Breast Cancer

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Exemestane
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Letrozole
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Tamoxifen Citrate
- **DRUG:** Toremifene Citrate

## Key facts

- **NCT ID:** NCT03238703
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-01
- **Primary completion:** 2023-03-14
- **Final completion:** 2025-03-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administrative closure based on sponsor recommendation, prior to subject enrollment
- **Last updated:** 2018-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238703, "Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03238703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*